Orasure Technologies earnings release, May 6, 2026

Orasure Technologies Inc (OSUR) · Form 8-K, Item 2.02 · Filed · SEC filing

OraSure Announces First Quarter 2026 Financial Results

BETHLEHEM, PA, May 6, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.

“Our Q1 results were consistent with our expectations, and revenue of $27.9 million was above the midpoint of our guidance range,” said Carrie Eglinton Manner, President and CEO of OTI. “We delivered gross margin expansion in Q1 and remain focused on leveraging our manufacturing capabilities and capacity to drive additional operating efficiencies.”

She continued, “OraSure is well positioned to accelerate our growth as we approach a series of regulatory and commercial milestones in 2026 and continue to transform our business through our strategy to decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private. Additionally, our strong balance sheet gives us the flexibility to pursue acquisitions and partnerships that strengthen our portfolio, while continuing to invest in R&D aimed at high‑value growth markets in order to drive long‑term value for shareholders.”

Financial Highlights ($ in 000’s, except per share amounts)

(1)

Includes Diagnostics, Sample Management Solutions, other products and services revenues, and non-product and services revenues.¹

NM – not meaningful

• Total net revenues for the first quarter of 2026 decreased 7% to $27.9 million from $29.9 million in the first quarter of 2025.

• Core revenues (all revenues excluding COVID-19, Molecular Services, and Risk Assessment Testing revenues) of $27.9 million in the first quarter decreased 0.5% year-over-year. Diagnostics revenues in the first quarter decreased 5% year-over-year to $16.9 million, with the decline attributable to lower revenue from our HCV tests. Sample Management Solutions revenues of $9.1 million in the first quarter decreased 0.6% year-over-year.

• GAAP gross margin was 42.3% in the first quarter of 2026 compared to 41.1% in the first quarter of 2025. Non-GAAP gross margin in the first quarter of 2026 was 43.4% and increased compared to 41.7% in the first quarter of 2025¹.

• GAAP operating loss in the first quarter of 2026 was $23.3 million compared to GAAP operating loss of $17.8 million in the first quarter of 2025. Non-GAAP operating loss was $19.0 million in the first quarter of 2026 compared to non-GAAP operating loss of $15.3 million in the first quarter of 2025.

• Cash and cash equivalents were $177 million as of March 31, 2026.

• OTI deployed $5 million during the first quarter to repurchase approximately 1.8 million shares of our common stock.

Recent Developments

• Appointed John D. Bertrand to our Board of Directors. Mr. Bertrand is a healthcare technology executive with more than a decade of experience driving AI-enabled innovation in diagnostics.¹

For additional information on non-GAAP financial measures and a reconciliation of the GAAP financial results to non-GAAP financial results, see the schedules below. A description of the adjustments made to the GAAP financial measures is included at the end of the schedules.²

• Published our 2025-2026 “OTI Cares” Impact and Governance report, which highlights our progress in advancing the impact of our sustainability and governance-related initiatives that are meaningful to our internal and external stakeholders.

Financial Guidance

The Company is guiding to Q2 2026 Total revenues of $27 million to $30 million.

Conference Call

The Company will host a conference call and audio webcast to discuss the Company’s first quarter 2026 results and certain business developments, beginning today at 5 p.m. Eastern Time. The call will include prepared remarks by management and a question and answer session.

A webcast of the conference call will be available on the investor relations page of OTI’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OTI’s website shortly after the call has ended.

Disclosure

OTI intends to use the Investor Relations Section of its website as a means of disclosing material non-public information (MNPI) and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor OTI’s website in addition to following its press releases, SEC filings, public conference calls, presentations, and webcasts.³

Financial Data (Unaudited, $ in 000’s, except per share amounts)⁴

Condensed Consolidated Balance Sheets (Unaudited, $ in 000’s)

Additional Financial Data (Unaudited, $ in 000’s)⁵

Consolidated Statement of Cash Flows (Unaudited, $ in 000’s)⁶

About OraSure Technologies

OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com

Financial statements

Income Statement

For the Three Months Ended March 31, — Financial Highlights ($ in 000’s, except per share amounts)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025For the Three Months Ended March 31, – % Change
Core Business (1)27,90728,050-1.0%
COVID-1918461-96.0%
Risk Assessment Testing1,420-100.0%
Total Net Revenues27,92529,931-7.0%

Income Statement

For the Three Months Ended March 31, — Includes Diagnostics, Sample Management Solutions, other products and services revenues, and non-product and services revenues.

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025For the Three Months Ended March 31, – % Change
Net revenues27,92529,931-7.0%
Gross profit11,80412,299-4.0%
Gross margin42.341.1
Non-GAAP gross profit12,10712,468-3.0%
Non-GAAP gross margin43.441.7
Operating loss-23,269-17,750NM
Operating margin-83.3-59.3
Non-GAAP operating loss-19,034-15,280NM
Non-GAAP operating margin-68.2-51.1
Net loss-22,377-16,040NM
Non-GAAP net (loss) income-17,022-13,139NM
Diluted GAAP EPS-0.32-0.21NM
Diluted Non-GAAP EPS-0.24-0.18NM

Income Statement

For the Three Months Ended March 31, — Financial Data (Unaudited, $ in 000’s, except per share amounts)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Results of OperationsNet revenues27,92529,931
Results of OperationsCost of products and services sold16,12117,632
Results of OperationsGross profit11,80412,299
Operating expenses:Research and development13,6549,603
Operating expenses:Sales and marketing6,7706,859
Operating expenses:General and administrative14,55614,102
Operating expenses:Change in the estimated fair value of acquisition-related contingent consideration93478
Operating expenses:Gain on sale of assets-993
Operating expenses:Total operating expenses35,07330,049
Operating expenses:Operating loss-23,269-17,750
Operating expenses:Other income1,5481,778
Operating expenses:Loss before income taxes and equity investment-21,721-15,972
Operating expenses:Income tax benefit-432-456
Operating expenses:Loss before equity investment-21,289-15,516
Operating expenses:Loss on equity investment-1,088-524
Operating expenses:Net loss-22,377-16,040
Loss per share:Basic-0.32-0.21
Loss per share:Diluted-0.32-0.21
Weighted average shares outstanding:Basic69,67574,867
Weighted average shares outstanding:Diluted69,67574,867

Income Statement

For the Three Months Ended March 31, — Financial Data (Unaudited, $ in 000’s, except per share amounts)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025For the Three Months Ended March 31, – % Change
Consolidated Net RevenuesDiagnostics16,86617,689-5.0%
Consolidated Net RevenuesSample Management Solutions9,0589,110-1.0%
Consolidated Net RevenuesOther products and services43432135.0%
Consolidated Net RevenuesCOVID-19 Diagnostics18457-96.0%
Consolidated Net RevenuesRisk Assessment Testing1,420-100.0%
Consolidated Net RevenuesNet product and services revenues26,37628,997-9.0%
Consolidated Net RevenuesNon-product and services revenues1,54993466.0%
Consolidated Net RevenuesNet revenues27,92529,931-7.0%

Income Statement

For the Three Months Ended March 31, — OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's, except per share amounts)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Net Revenues27,92529,931
GAAP Cost of Products and Services Sold16,12117,632
GAAP Gross Margin42.341.1
Stock compensation190169
Amortization of acquisition-related intangible assets48
Reduction in workforce severance65
Non-GAAP Cost of Goods Sold15,81817,463
Non-GAAP Gross Margin43.441.7
GAAP Operating Loss-23,269-17,750
Stock compensation2,7682,687
Amortization of acquisition-related intangible assets10555
Reduction in workforce severance1,269
Gain on sale of assets under product line discontinuance-750
Change in fair value of acquisition-related contingent consideration93478
Non-GAAP Operating Loss-19,034-15,280
GAAP Net Loss-22,377-16,040
Stock compensation2,7682,687
Amortization of acquisition-related intangible assets10555
Reduction in workforce severance1,269
Gain on sale of assets under product line discontinuance-750
Change in fair value of acquisition-related contingent consideration93478
Loss on equity investment1,088524
Tax effect of non-GAAP adjustments32-93
Non-GAAP Net Loss-17,022-13,139
GAAP Loss Per Share:-0.32-0.21
Non-GAAP Loss Per Share:-0.24-0.18
Diluted Shares Outstanding69,67574,867
Diluted Shares Outstanding Used For Computing Non-GAAP Loss Per Share69,67574,867

Balance Sheet

March 31, 2026 — Condensed Consolidated Balance Sheets (Unaudited, $ in 000’s)

March 31, 2026December 31, 2025
AssetsCash and cash equivalents176,964199,278
AssetsAccounts receivable, net24,80722,203
AssetsInventories30,30731,060
AssetsOther current assets8,7039,367
AssetsProperty, plant and equipment, net37,85739,179
AssetsIntangible assets, net18,94019,046
AssetsGoodwill43,04743,363
AssetsInvestment in equity method investee24,86825,956
AssetsOther noncurrent assets13,67613,716
AssetsTotal assets379,169403,168

Cash Flow

For the Three Months Ended March 31, — Additional Financial Data (Unaudited, $ in 000’s)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Capital expenditures913420
Depreciation and amortization2,3412,808
Stock-based compensation2,7682,687
Cash used in operating activities-13,895-19,733

Cash Flow

For the Three Months Ended March 31, — Consolidated Statement of Cash Flows (Unaudited, $ in 000’s)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
OPERATING ACTIVITIES:Net loss-22,377-16,040
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation2,7682,687
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization2,3412,808
Adjustments to reconcile net loss to net cash used in operating activities:Other non-cash amortization-82-37
Adjustments to reconcile net loss to net cash used in operating activities:Provision for credit losses66-248
Adjustments to reconcile net loss to net cash used in operating activities:Unrealized foreign currency (gain) loss-153194
Adjustments to reconcile net loss to net cash used in operating activities:Interest expense on finance leases32
Adjustments to reconcile net loss to net cash used in operating activities:Loss on equity investment1,088524
Adjustments to reconcile net loss to net cash used in operating activities:Deferred income taxes-354-384
Adjustments to reconcile net loss to net cash used in operating activities:Gain on sale of fixed assets-780
Adjustments to reconcile net loss to net cash used in operating activities:Change in the estimated fair value of acquisition-related contingent consideration93478
Changes in assets and liabilities:Accounts receivable-2,6212,413
Changes in assets and liabilities:Inventories714-1,482
Changes in assets and liabilities:Prepaid expenses and other assets583-2,075
Changes in assets and liabilities:Accounts payable4,104-726
Changes in assets and liabilities:Deferred revenue-645-451
Changes in assets and liabilities:Accrued expenses and other liabilities577-6,616
Changes in assets and liabilities:Net cash used in operating activities-13,895-19,733
INVESTING ACTIVITIES:Proceeds from sale of assets790
INVESTING ACTIVITIES:Purchases of property and equipment-913-420
INVESTING ACTIVITIES:Net cash (used in) provided by investing activities-913370
FINANCING ACTIVITIES:Cash payments for finance lease liabilities-21-12
FINANCING ACTIVITIES:Repurchase of common stock-5,000
FINANCING ACTIVITIES:Payment of taxes related to net share settlement of equity awards-1,261-941
FINANCING ACTIVITIES:Net cash used in financing activities-6,282-953
FINANCING ACTIVITIES:EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH-1,224122
FINANCING ACTIVITIES:NET DECREASE IN CASH AND CASH EQUIVALENTS-22,314-20,194
FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD199,278267,763
FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, END OF PERIOD176,964247,569
Full release

Forward Looking Statements... (truncated)opment and manufacturing activities, regulatory submissions and authorizations, revenue growth and guidance, expected revenue from government orders, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to market and sell our products and services, whether through our internal, direct sales force or third parties; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; significant customer concentrations that exist or may develop in the future; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; impact of replacing distributors; inventory levels at distributors and other customers; our ability to achieve its financial and strategic objectives and increase our revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of our products and services; ability to achieve the anticipated benefits from the BioMedomics transaction; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to achieve and maintain sustained profitability; ability to increase our gross margins; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents, trade secrets and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms on international sales; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to⁷ obtain needed raw materials and components; cybersecurity incidents and other disruptions involving our computer systems or those of our third-party IT service providers, suppliers and customers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

Statement Regarding Use of Non-GAAP Financial Measures... (truncated) reporting periods, while excluding certain expenses that may not be indicative of the Company’s recurring core business operating results. In addition, management believes these non-GAAP financial measures are useful to investors both because they (1) allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) are used by OraSure’s institutional investors and the analysis community to help them analyze the health of OraSure’s business. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.⁸

OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's, except per share amounts)

The following is a description of the adjustments made to GAAP financial measures:

• Stock Compensation: non-cash equity-based compensation provided to OraSure employees and directors

• Amortization of acquisition-related intangible assets: represents recurring amortization charges resulting from the acquisition of intangible assets associated with our business combinations

• Reduction in workforce severance: termination benefits associated with the Company’s workforce reduction associated with certain business

• Gain on sale of assets under product line discontinuance: represents the gain on the sale of fixed assets associated with the risk assessment line of business that was discontinued and sold to a 3rd party

• Change in fair value of acquisition-related contingent consideration: changes in the fair value of contingent consideration liability associated with an adjustment for the passage of time

• Loss on equity investment: we have excluded our proportionate share of our equity method investee’s net loss as we do not have direct control over the investee’s operations or resulting revenue and expenses

• Tax impact associated with non-GAAP adjustments: tax expense/(benefit) due to non-GAAP adjustments

A reconciliation of our non-GAAP measures to their most directly comparable GAAP measures can also be found at: https://orasure.gcs-web.com/gaap-non-gaap-reconciliation

###⁹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Orasure Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.